about
Localization of BRCA1 protein in breast cancer tissue and cell lines with mutationsMolecular biology of lung cancer: clinical implicationsFailure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroEvolution of the cancer genomeBreast cancer chemoprevention: old and new approachesChoices have consequences: the nexus between DNA repair pathways and genomic instability in cancerOn/off-switchable anti-neoplastic nanoarchitectureExome sequencing reveals a potential mutational trajectory and treatments for a specific pancreatic cancer patient.Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell linesWhat are we learning from the cancer genome?ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.Triple-negative and basal-like breast cancer: implications for oncologists.The multitude of molecular analyses in cancer: the opening of Pandora’s box.Recent progress in targeting cancer.NCI's provocative questions on cancer: some answers to ignite discussion.EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.Present status and problems on molecular targeted therapy of cancerSynthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival.Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.DNA repair in cancer: emerging targets for personalized therapy.Exploring the genomes of cancer cells: progress and promise.The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets.Opportunities and challenges provided by crosstalk between signalling pathways in cancer.Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial CarcinomaAn in-silico approach to predict and exploit synthetic lethality in cancer metabolism.Protease addiction and synthetic lethality in cancer.Cancer/testis antigens as molecular drug targets using network pharmacology.
P2860
Q24308016-A5EF90F0-BA51-4FF9-9FD3-A46130E392A6Q24610335-465A18B2-2418-4B90-A02B-8B2F6E428BC1Q24615499-635C9224-FCC5-4A5F-8A22-FCC746E79841Q27020991-227C9DC1-8C4E-4413-BDF8-519EEABF7F4EQ27693259-EA64C24F-3E9C-40AA-92E5-6B50B95FB3EAQ28066464-B02AF50F-16CD-4388-B1AA-15F2D23DA27EQ28389792-6A782910-BDE6-4D55-B709-7861D2FA03C0Q33583509-C5E83457-A92E-4861-B672-1AFB162D289BQ33739351-3DB4A86A-D41E-438E-9273-F629865EECDBQ34060031-23503E64-08A1-4136-A013-CF0F2E9FB103Q34213994-7623A3C8-1515-4ABB-A740-7D14F028671CQ34249365-E8A47956-4976-4A9F-9C22-C576F4CF3374Q34589207-E42FDADF-3D11-47CC-BC2A-BC3B8208B231Q34608239-B1488FF0-80E5-4817-8B33-C2802900DE8CQ35145642-5FD80120-7DF5-48BB-980E-0FFDE4073143Q35332888-29E51261-511B-4030-9187-38A8041D8F51Q35740782-DAB0C3E6-3E10-45EF-A12F-7C6D7DBA2029Q35764401-A062B5F8-B8C3-4DE3-BA08-3D74ABEA10ABQ35873250-6FEBA2B7-BBC5-46F7-ACC3-756A58234D07Q35877737-FC2F12A3-F3C1-4191-BBE3-9203414BBD0AQ36120262-EA7C6073-2EC4-4794-A520-D2DFA9812018Q36546455-03AE567F-4BDD-4A0E-9D59-FBBD9996916EQ36738376-A36977C9-23A8-4E3A-9B76-50C1507AC411Q37190452-96F28BC9-CABE-4046-8367-5AF44DDFAC49Q37524037-C7550802-D85E-4FD2-910A-9F2CE0E905D5Q37600799-76C77523-1B2E-4B5B-AFF2-ABFE9C067494Q37857590-4CAEF455-1F30-4E2E-9094-3C9D8C38C2DCQ37983690-3E12E60D-B4F8-40B4-A54A-7E8EC87F3318Q38066230-97511011-69FB-447B-A0D6-29169AC80B10Q38087850-63487709-FA0A-46FE-8968-62CAC3E2A9F8Q38422476-06004D2B-2C08-4BE7-8FF2-3DF11B517973Q38485894-4DE88029-BA5D-491E-B522-02CE97C39FFCQ38628334-9506982E-BF5B-47B4-8CA0-6DEA4C63BECAQ38974991-28C717D7-767F-4283-9555-65623C5F477AQ39112227-5827D148-5499-44A5-BE76-4B373A6AA96BQ41002840-748DFAB0-A9D5-4353-99D6-EF4A417E830BQ41632506-0C0CCC33-E465-4860-9142-5E8D1AB41173Q42174996-FDF59C8D-F89C-48C2-A1B0-74C159138525Q49011456-B1F2026C-7D00-4713-A136-231074F1CEE4
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Synthetic lethal approaches to breast cancer therapy.
@en
Synthetic lethal approaches to breast cancer therapy.
@nl
type
label
Synthetic lethal approaches to breast cancer therapy.
@en
Synthetic lethal approaches to breast cancer therapy.
@nl
prefLabel
Synthetic lethal approaches to breast cancer therapy.
@en
Synthetic lethal approaches to breast cancer therapy.
@nl
P2860
P1476
Synthetic lethal approaches to breast cancer therapy.
@en
P2093
Farah L Rehman
P2860
P304
P356
10.1038/NRCLINONC.2010.172
P407
P577
2010-10-19T00:00:00Z